Introduction
A high body mass index (BMI) is an important risk factor for the progression of type 2 diabetes mellitus (T2DM) due to its association with metabolic syndrome, which is responsible for complications such as systemic arterial hypertension and dyslipidemia 1, 2 .
In the approach proposed for greater control of T2DM, bariatric surgery is highly regarded, as it may prevent or cure T2DM in morbidly obese patients [3] [4] [5] [6] .
All disabsortive methods of bariatric surgeries have demonstrated a marked impact on T2DM, although with varying degrees of effectiveness 7, 8 .Among bariatric procedures, two techniques are considered the most effective: the Roux-en-Y gastric bypass (mixed technique) and the biliopancreatic diversion (disabsortive technique) 9 .
Patients who have undergone gastrectomy for benign conditions do not develop obesity and remain thin for life.
Furthermore, morbidly obese patients who undergo biliopancreatic diversion, Roux-en-Y gastric bypass procedures, and vertical banded gastroplasty plus truncal vagotomy lose more weight compared to patients subjected to vertical banded gastroplasty alone 10, 11 .
Pinkney and Kerrigan 12 observed that the patient often exhibits glycemic control a few days after surgery, long before the weight loss becomes significant, although the weight loss is directly correlated with decreases in insulin resistance and blood glucose level [13] [14] [15] .
Kashyap et al. 16 studied the early effects of bariatric surgery on beta cell function and insulinotropic hormone action in obese patients with T2DM before the weight loss occurred.
They observed that gastric bypass resulted in better T2DM control before the weight loss occurred, with most patients suspending the use of antidiabetogenic medication, probably due to an increase in the endocrine response of beta cells, an event that is attributed to the action of incretins due to the increase in glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) levels caused by the surgery.
Furness et al. 17 showed that truncal vagotomy alone is able to reduce food intake and consequently leads to weight loss in humans and animals. These authors also found that rats subjected to vagotomy reduced their daily food intake and exhibited a fat mass reduction of 20% at 4 weeks after the vagotomy, an effect that is attributed to the loss of vagal afferent pathways responsible for stimulating appetite.
The objective of this study was to evaluate the effectiveness of the biliopancreatic diversion surgery with duodenojejunal exclusion in combination with truncal vagotomy in T2DM patients with overweight or class I or II obesity.
Methods
The research protocol for this study was approved by the Research Ethics Committee of the Institute for Medical Assistance to State Public Servant (IAMSPE) (protocol number 063/09).
Ten adult patients of both genders from Candido Rondon
Hospital (Ji-Parana-RO, Brazil) with diagnosis of T2DM were selected for the study. The average age was 51.9 years (range, 42
to 62 years). Seven patients were females, and three were males.
All patients were either overweight or had class I or class II obesity according to the World Health Organization (WHO) criteria 10, 15, 18 and had an average preoperative BMI value of 34.5 kg/m² (range 27 to 39 kg/m 2 ).
All patients were operated upon by the same surgeon (EA) and underwent biliopancreatic diversion with duodenojejunal exclusion and truncal vagotomy. The inclusion criteria were adult patients with BMI<40 kg/m², C-peptide serum levels >1 ng/mL, anti-glutamic acid decarboxylase (anti-GAD) serum levels <1 U/mL, and acceptance of the terms of informed consent. The exclusion criteria were the presence of malignancy in any location, pediatric age, C-peptide serum levels ≤1 ng/mL, anti-GAD serum levels ≥1 U/mL, and the rejection of the terms of informed consent.
The average preoperative fasting blood glucose was 173.9±52.4 mg/dL. Before the surgery, seven patients used hypoglycemic agents: Four used metformin or glibenclamide, and the other three used insulin to control the blood glucose levels.
During the preoperative period, the average C-peptide level was 2.9 ng/mL (range, 1 to 5.3 ng/mL), and all patients had C-peptide levels greater than or equal to 1 ng/mL. The average anti-GAD level was 0.6 U/mL (range, 0.1 to 1.0 U/mL). The average glycosylated hemoglobin was 8.2% (range, 6.2% to 11%).
The following laboratory tests were obtained in the preoperative and postoperative periods: plasma levels of fasting glucose (mg/dL), C-peptide level (ng/mL), anti-GAD (U/mL), glycosylated hemoglobin (%), hemoglobin (g/dL), hematocrit 
Postoperative treatments
During the first 30 postoperative days, the patients were subjected to capillary blood glucose tests every 6 hours. In the subsequent 60 days, the test was performed twice a day.
After hospital discharge, the patients were monitored at the outpatient clinic with scheduled follow-ups at one, three, six, nine and 12 months. All patients received the same dietary guidelines. Initially, the patients were on a liquid diet plan until food was reintroduced during the postoperative period. At 17 days after the surgery, the patients were given a liquid and soft diet, and 30 days after the surgery, solid foods, proteins, iron, and calcium were added to the diet plan. Control laboratory tests were conducted at one, three, six, and 12 months after the surgery.
Statistical analysis
In the descriptive analysis of the data obtained, the 
Results
The mean operation time was 90 minutes. There were no intra-operative complications. The average length of hospital stay after surgery was 33.6 hours (range 24 to 72 hours). There were no cases of gastroparesia, increased gastroesophageal reflux, or anastomotic ulcers in the patients participating in this study.
There were two complications during the early postoperative period: one patient had bleeding at the gastroenteric suture line, and another patient had a subphrenic abscess. Both complications occurred seven days after hospital discharge.
The first patient was treated by endoscopic sclerosis with monoethanolamine oleate on the suture line and transfusion of two units of whole blood. The subphrenic abscess was treated by intercostal drainage and antibiotic therapy, which resulted in clinical improvement.
All patients used subcutaneous insulin during the postoperative period for no more than two months. A continuous and progressive reduction in fasting glucose levels was observed.
The blood glucose levels were normalized in all patients at the end of 12 months after the surgery, and there was no need for the use of medications after this period (Table 1) .
At 12 months after surgery, glycosylated hemoglobin was reduced in 80% of patients (Table 2) ; the average BMI reduction was 7.0±1.5 kg/m² (range, 5 kg/m² to 12 kg/m²) ( Table   3 
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Discussion
One of the greatest benefits of bariatric surgery is the resolution of T2DM in approximately 50% to 80% of cases 18 . The changes in the secretion of incretin hormones produced in the small intestine and their effects on insulin and glucagon production may be a mediator of the significant improvement in blood glucose levels after gastric bypass surgery, which would not show the same effects when compared to weight loss caused by diet or restrictive surgeries [19] [20] [21] .
GIP and GLP-1 are secreted by K cells in the duodenum and L cells in the ileum, respectively. These two incretins are responsible for approximately 50% of postprandial secretion of insulin 21, 22 .
Laferrère et al. 19, 20 found that patients subjected to gastric bypass exhibited a significant 5-to 10-fold increase in postprandial GLP-1 or after the oral intake of glucose. However, the GIP levels did not show significant changes after the same surgical procedure was performed. Nevertheless, the increase in GLP-1 levels observed soon after gastric bypass surgery remained constant 3 years after the surgical procedure.
It has been shown that bariatric surgery promotes the control or improvement of T2DM 9, 12, 15, 16, 18, 23 . Among the variations of this type of surgery, the disabsortive techniques are considered the most effective 23 . Conventional gastrointestinal surgeries for obesity also have yielded marked improvements in T2DM, resulting in the normalization of blood glucose and glycosylated hemoglobin levels and the subsequent suspension of hypoglycemic drug use 14, 24 .
It was observed that the improved glycemic control resulting from surgeries that exclude the duodenum and jejunum occurs very fast (approximately five to six days after the procedure), when significant body weight loss or reduction in calories intake still has not occurred 23 .
While investigating the mechanisms of action for gastrointestinal diversion procedures using duodenojejunal bypass, it was suggested that the exclusion of the duodenum and proximal jejunum would change nutrient movement, thus preventing the stimulation of the inappropriate signal that would promote insulin resistance 13, 25, 26 . Rubino et al. 25 reported that duodenal exclusion of nutrient movement is the critical component for this reduction and subsequent control of diabetes mellitus.
Geloneze et al. 26 compared the potential advantages of the duodenojejunal exclusion surgery. Thus, a group of patients was operated upon using this technique and was compared to another paired control group that received the standard medical treatment for T2DM. At the end of 24 weeks after the surgery, the patients who were operated upon exhibited a significant decrease in blood glucose and a lower average daily insulin requirement (93% vs. 29% of the control group). These authors concluded that duodenojejunal exclusion is an effective and superior method to the standard treatment for the control of T2DM.
In this study, using this technique, which was used in conjunction with truncal vagotomy in patients with T2DM
and overweight or class I or II obesity, resulted in a significant proportion (80%) of patients with decreased blood glucose levels in the first month after the surgery, with one patient reaching normal levels.
Kindel et al. 27 preoperative period to 12 months after the surgery was significant (p=0.001).
Ramos et al. 28 found that patients who underwent duodenojejunal exclusion exhibited a decrease in BMI up to 3 months after surgery, and their weights stabilized between 3 and 6 months after surgery. There was a significant reduction (p<0.001)
in fasting blood glucose (43.8%) and HbA1c (22.8%) levels up to the sixth month.
In the case series described in this report, all patients exhibited a significant reduction in their average BMI value, which decreased from 35±4.0 kg/m² to 28±3.1 kg/m² over 1 year. Thus, as occurs in vagal blocking, the weight loss was ready expected due to the truncal vagotomy. All patients experienced early satiety and reduced their volume of caloric intake.
Roux et al. 29 observed that the transection of the vagus nerve abolished the orexigenic effect of ghrelin. These authors observed that the administration of peripheral ghrelin leads to increased food intake and GH release in humans. Thus, it is believed that ghrelin increases appetite. These authors also observed that after a gastrectomy, the plasma levels of ghrelin are reduced to at least 50% of the initial values.
Souza et al. 
Conclusions
The biliopancreatic diversion with duodenojejunal exclusion technique in combination with truncal vagotomy in patients with T2DM and overweight or class I or II obesity has the potential to be an option for the treatment of T2DM. However, controlled clinical studies are still required, including a control group that does not undergo truncal vagotomy, and with an adequate number of patients to confirm the encouraging results obtained in this case series.
